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PRELIMINARY AND SHORT REPORT
A SCREENING TEST FOR ANTI-INFLAMMATORY ACTIVITY USING HUMAN SKIN*
JosEPH A. WITKOW5KI, M.D. AND ALBERT M. KLIOMAN, M.D., Pn.D.
This paper describes a simple means of detecting
agents with anti-inflammatory activity.
MATERIALS AND METHODS
Adult, male subjects, preferably Negroes, are
selected who give a brisk follicular pustular re-
sponse to a eroton oil patch test. Although
subjects who form pustules readily are in the
minority, once found they may be used again and
again. The pustule-provoking stimulus consists of
applying a plastic Band-aidt moistened with 0.25
ml. of a 25% eroton oil in acetone solution just
prior to use. The intcrscapular area of the back
was found most suitable as a test area. Circular
test sites 1.5 cm. in diameter are marked out with
a dye after defatting the skin by rubbing with
ether soaked gauze.
The test agents are dissolved or suspended in a
vehicle containing carboxymethyl cellulose, 10
mg/mi and polysorbate 80, 4 mg/mI. Insoluble
substances are homogenized in a grinding vessel of
pyrex glass with a Teflon pestle (1). The injections
were made intradermally, always in a volume of
0.5 ml. The quantity per injection for preliminary
screening was 0.5 to 2.0 trig. This was arbitrarily
selected by reason of its being in the range of
activity of hydrocortisone, providing some stand-
ard of comparison.
To do the test, the injection is made into the
center of the circular test Site which is then imme-
diately covered with the croton oil patch. The
patch is removed at 24 hours and pustule suppres-
sion is estimated to the nearest 25%. The control
site is injected with 1 mg. of cholesterol suspended
in the above vehicle. The test agents must not in
themselves produce inflammation. Four subjects
were used for each test substance, but we now
consider two sufficient. The results arc highly
consistent.
REsULTs
Table 1 summarizes the anti-inflammatory
effects of a variety of agents, mainly corticos-
teroids which were tested by this method. As a
rule the greatest activity was shown by those
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compounds which clinical experience has proved
to be potent anti-inflammatory agents. Triamcino
lone, for instance, was the most active of all. For
a number of these compounds the results of testing
by the granuloma pouch technic were known. The
agreement was quite good and in no case was there
a marked discrepancy.
For practical purposes, an agent may be satis-
factorily rated by this test in terms of being more
or less active than standard compounds such as
hydrocortisonc and prednisolonc. The greater
potency however of the acctatcs of hydrocortisone
and 16 a OH fluorohydrocortisonc over the corre-
sponding uncsterificd bases is not a genuine ex-
pression of superiority when related to clinical or
biological activity. There is no justification for
thinking that highly accurate ratios of potency
can be established from a screening procedure of
this sort.
Of modest interest is the finding that progester-
one and ACTH both had slight anti-inflammatory
activity. Although Goldman etat (2) found corti-
sone inactive when injected into inflammatory
skin lesions, it had some activity by the present
method but only in high amounts bordering on the
quantity producing inflammation. Observations
on a cortisone were hampered by similar limita-
tions. This method is inappropriate for agents in
this class of lower activity.
It is known that crystals of corticostcroids
persist for months at the injection site. A neat
biological confirmation of this was had by demon-
strating pustule suppression, though of lesser
degree, a month or more after injection. It is
interesting to note that soluble congencrs of
corticosteroids were considerably less active than
the corresponding insoluble compounds. Further-
more, the pustule suppression was transient, more
in the nature of a delaying action. For example,
pustulcs began to appear in 48 hours which were
not present at 24, and by 72 hours the full crop of
pustulcs emerged in the uninhibited state. More-
over, there was no inhibition when the croton oil
patch was applied three or more days after injec-
tion. This lesser, transient activity is doubtlessly
due to loss of the material by diffusion and absorp-
tion. A related example of this phenomenon was
the lesser, more transient activity of insoluble
corticostcroids injected along with hyaluronidase.
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TABLE 1
Pustule suppression by steroids
Substance oSolubility*
% Inhibition (mg)
100% 75% 50% 25% 0%
Hydrocortisone (170H corticosterone) I 1.0 0.5 0.1
Hydrocortisone acetate I 0.5 0.1 0.05
'Hydrocortisone acetate (prednisolone acetate) I 0.05 0.03 0.01
Cortisone acetate (11 dehydro-170H cortico
sterone) I 25.0 15.0 12.5 10.0
'Cortisone (prednisone) I 25.0 12.5 10.0
9aFluorohydrocortisone acetate I 0.1 0.05 0.01
16s0H fluorohydrocortisone I 5.0 1.0 0.5 0.1
l6aOH fluorohydrocortisone acetate I 0.5 0.1 0.05 0.01
Triamcinolone (Pafluoro 16a(0H'hydrocorti-
sone) I 0.025 0.01 0.005 0.001
9a21 difluoro 21 desoxyhydrocortisone I 2.0 0.2 0.02
Methyl-prednisolone (Medral) I 0.05 0.01 0.005
Fluoromethyl-prednisolone (fluoro Medral) I 0.1 0.05 0.01
ACTH I 37.5u 25.Ou 20.Ou
11 desoxycorticosterone I 20.0
Progesterone I 5.0 2.5
9aBromo 11 keto progesterone I 5.0 2.5
9afluoro 1130H progesterone I 5.0 2.5 1.0
9a2l Difluoro4pregnene11f317adiol3,20-dione... I 5.0 2.5 1.0 0.5
Testosterone I 5.0
11$ 0114, 17 dimethyl testosterone I 10.0
16a0H androstendione I 5.0
Estradiol cyclopentyipropionate I 1.0
Hydrocortisone sodium succinate S 20.0 10.0 5.0 1.0
Prednisolone sodium succinate S 10.0 5.0 2.0 0.5
Prednisolone hemisuccinate (Meticortelone) S 10.0 5.0 2.0 0.5
Prednisolone phosphate S 10.0 2.5 0.5 0.1
* I—insoluble.
S—soluble.
FIG. 1. Left: Complete pustule suppression by 2 mg. of hydrocortisone. Right: No suppression in
cholesterol control.
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For these reasons, the twenty-four hour reading
is the most significant for soluble agents.
DISCUSSION
To date only agents having the potency of
hydrocortisone or greater have exhibited clinical
anti-inflammatory activity when applied topi-
cally. However, it would be hazardous to draw
inferences about Comparative topical activity from
the pustule suppression test. Topical effectiveness
will principally depend on penetration from the
surface. The skin's permeability to the test sub-
stance will, therefore, be decisive. It is conceiv-
able that an agent, effective by injection, might
be totally inactive topically. Conversely, effective
topical agents would almost certainly exhibit
anti-inflammatory activity by injection. Accord-
ingly, an experimental method of topical testing
for anti-inflammatory activity would not only be
meaningful but considerably simpler. Unhappily,
our efforts to accomplish this have so far failed.
We have not produced an experimental inflamma-
tion which could be consistently moderated by
topical steroids of known effectiveness. The
methods of Scott and Kalz, (3) and Wells, (4)
utilizing scotch tape stripping, ultra-violet irra-
diation and chemical irritancy were futile in our
hands.
The advantages of the pustule inhibition test
are:
1. Anti-inflammatory activity is measured
directly and not by some proximate pharmaco-
dynamic property possessed by corticosteroids
such as eosinopenia, glycogen storage, etc.
2. Small amounts in the order of a few milli-
grams are sufficient. This is an important factor
in the early stages of drug development.
3. The test is completed in 24 hours.
5WUMARv
Pustule formation induced by croton oil on
human skin is suppressed by prior intradermal
injection of corticosteroids. This is the basis of a
simple, rapid screening method for detecting
agents with anti-inflammatory activity.
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